In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Anika SchickEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden. anika.schick@astrazeneca.com.ORCID 0009-0003-4200-7390 Marc San Jose GraciaSanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Industriepark Höchst, Frankfurt am Main, Germany.
Hans Christian D HammershøjInterdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, Aarhus, Denmark.
Johan BroddefalkMedicinal Chemistry, CVRM, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0009-0002-3971-4652 Pablo Martínez-PardoEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-4819-0854 Vitus J EnemærkeInterdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-3099-2544 Lena von SydowMedicinal Chemistry, R&I, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Anna HolubSanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Industriepark Höchst, Frankfurt am Main, Germany.
Ranganath GopalakrishnanMedicinal Chemistry, CVRM, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Kim S MühlfenzlEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-3700-0891 Troels SkrydstrupInterdisciplinary Nanoscience Center (iNANO) and Department of Chemistry, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-8090-5050 Charles S ElmoreEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, MA, USA. chad.elmore@astrazeneca.com.ORCID 0000-0001-7434-8307 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Peptides constitute a well-established and rapidly expanding field in the contemporary pharmaceutical drug landscape. Studies with
Indexed as
Carbon RadioisotopesLysinePeptidesTritiumIsotope LabelingSemaglutideCarbon RadioisotopesLysinePeptidesSemaglutideTritium
Identifiers
PMID42285941
PMCPMC13272800
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390